Navigation Links
Sanofi-aventis Sends Letter to Genzyme Seeking Clarification on Potential Board Actions
Date:11/8/2010

PARIS, Nov. 8, 2010 /PRNewswire/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that it has sent a letter to Genzyme Corporation (Nasdaq: GENZ) requesting that Genzyme clarify its position on a number of potential Board actions raised in Genzyme's Schedule 14D-9.

Sanofi-aventis' letter also notes that it is encouraged by Genzyme's decision to "probe and evaluate alternatives" including contacting third parties but observes that sanofi-aventis has not been contacted by Genzyme or its advisors. Sanofi-aventis continues to remain interested in working with Genzyme on a constructive basis and is committed to a mutually agreeable transaction.  

Below is the full text of the letter that was sent to Genzyme, which is also being filed with the U.S. Securities and Exchange Commission.November 8, 2010VIA EMAIL, TELECOPIER AND DHLMr. Henri TermeerChairman, President and Chief Executive OfficerGenzyme Corporation500 Kendall StreetCambridge, Massachusetts 02147USADear Henri,

Now that Genzyme's third-quarter earnings have been released, you have had the opportunity to speak to shareholders regarding Genzyme's business and prospects (including the detailed presentation to analysts and investors on October 22) and the market has had a chance to digest and react to all of this information, we would again like to request that you meet with us to discuss our proposal to acquire Genzyme.  We continue to believe that our proposal is compelling for your shareholders and would provide them with immediate and substantial value that reflects the potential of Genzyme's business and pipeline.  

You have publicly disclosed that Genzyme's Board has authorized management and the company's advisors to "probe and evaluate alternatives" for Genzyme and its assets, inclu
'/>"/>

SOURCE sanofi-aventis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Covance and sanofi-aventis Finalize Agreements for 10-year Strategic R&D Alliance
2. Sanofi-aventis to Acquire BMP Sunstone Creating a Strong Consumer Healthcare Platform in China
3. Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis
4. Sanofi-aventis Commences Tender Offer to Acquire All Outstanding Shares of Genzyme for $69 per Share in Cash
5. Covance and Sanofi-Aventis Sign Definitive Agreements for 10-Year Strategic R&D Alliance
6. European Hospital Anticoagulant Market Dominated by Sanofi-Aventiss Clexane
7. Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile
8. Sanofi-aventis Announces Non-Binding Offer to Acquire Genzyme
9. Sanofi-Aventis and Novalar File Marketing Authorization Application for OraVerse® in Five Key European Countries
10. Oramed Pharmaceuticals and sanofi-aventis Enter Into an Agreement for the Insulin Supply of Orameds Oral Insulin Capsules
11. Sanofi-aventis Successfully Completes The Acquisition of Chattem, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... N.J. , July 30, 2015 Eisai ... in the United States , European ... FDA, EMA and MHLW, respectively) for eribulin, for the ... who have received prior chemotherapy for advanced or metastatic ... on data from a pivotal global Phase 3 clinical ...
(Date:7/30/2015)... July 30, 2015 Future Market ... titled, "Continuous Glucose Monitoring Systems Market: Global Industry Analysis ... report, the global continuous glucose monitoring systems market was ... expected to reach US$ 788.4 Mn by 2020, registering ... to 2020. Global continuous glucose monitoring systems ...
(Date:7/30/2015)... N.J. , July 30, 2015  Medimetriks ... completed the second Phase III clinical study for ... for impetigo.  Medimetriks owns the exclusive U.S. rights ... global trial, conducted at 44 centers with an ... pediatric patients aged 2 months and older with ...
Breaking Medicine Technology:Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
... , , Part ... SPRING, Md., Nov. 19 The U.S. Food and ... called the International Internet Week of Action (IIWA), intended ... http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) , During the effort, the FDA,s ...
... NEWS, Va., Nov. 19 Breast-Specific Gamma Imaging/Molecular Breast ... highly esteemed organizations for the fight against breast cancer: ... College of Surgeons. Both societies published articles supporting the ... early detection of breast cancer. , "These endorsements reinforce ...
Cached Medicine Technology:UPDATE: FDA Issues 22 Warning Letters to Web site Operators 2Esteemed Endorsements Recognize Promising Future of Breast-Specific Gamma Imaging (BSGI) 2Esteemed Endorsements Recognize Promising Future of Breast-Specific Gamma Imaging (BSGI) 3
(Date:7/30/2015)... ... 2015 , ... The Mesothelioma Applied Research Foundation (Meso Foundation) ... of 2015’. The bill was introduced in Congress yesterday by Representatives John Katko ... Joe Kennedy (D-MA), and Leonard Lance (R-NJ). The purpose of the bill is ...
(Date:7/30/2015)... ... ... On July 23rd Clay Today Online reported the state of ... prison system, which has amassed largely enough throughout the years. Florida is the third ... Obama’s recent reduction of non violent drug offender’s prison sentences, Florida is beginning to ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... Acting Administrator Chuck Rosenberg’s announcement of the reinstitution of National Prescription Drug Take-Back ... 26, 2015 from 10:00 AM to 2:00 PM local time. On the 26th, ...
(Date:7/30/2015)... ... , ... Bird B Gone, the leader in bird control products for commercial, ... pest birds from the AC units and ventilation systems on hospital roofs. Bird droppings ... West Nile virus. When these droppings dry, the fine powder can be carried into ...
(Date:7/30/2015)... ... July 30, 2015 , ... Summer is the dry eye season, ... that a particularly long, dry and hot 2015 summer season and the dry eye ... advocate Sharon Kleyne will discuss the 2015 summer season and identify the primary dry ...
Breaking Medicine News(10 mins):Health News:Bill to Create Patient Registry for Deadly Cancer Introduced in Congress 2Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 2Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 3Health News:AAPCC Supports National Prescription Drug Take-Back Day 2Health News:AAPCC Supports National Prescription Drug Take-Back Day 3Health News:Bird B Gone’s New Bird Hazing System Keeps Disease-Carrying Bird Droppings Out of Hospitals 2Health News:Fresh Water Advocate Sharon Kleyne Warns to Be Extra Cautious About Dry Eye “Hot Spot” Cities In Hot Dry Summer of 2015 2Health News:Fresh Water Advocate Sharon Kleyne Warns to Be Extra Cautious About Dry Eye “Hot Spot” Cities In Hot Dry Summer of 2015 3
... the nation,s leading,supplier of replacement medical repair parts for ... companies in Ohio by the Case Western,Weatherhead School of ... growth rate exceeding 1000% and has won the award ... clearly one of our region,s most prestigious,honors," said PartsSource ...
... could yield targeted treatments for leukemia, bone marrow transplants ... of all human blood cells has been identified by ... to new treatments for blood cancers and other blood ... progenitor, is the initial offspring of a blood-forming stem ...
... Inc.,(NYSE: BMR ) today announced that its board ... $0.31 per share of common stock. The,dividend is equivalent ... BioMed also announced that its board of directors ... company,s 7.375% Series A Cumulative,Redeemable Preferred Stock for the ...
... WASHINGTON, Dec. 12 Speaker Nancy Pelosi,Majority Leader Steny ... Rahm Emanuel held a news conference late this afternoon ... news conference, President,Bush vetoed the bill. Below are the ... that later today that the President,will veto the SCHIP ...
... experts say recall shouldn,t be health threat , , WEDNESDAY, ... 1.2 million doses of a common childhood vaccine due ... vaccine does not pose a health threat, U.S. health ... recalled two lots of the Haemophilus influenzae ...
... A new school curriculum,that counters abuse of prescription ... a press conference today in Washington, D.C. The,curriculum ... as presentations,for parents. This curriculum was created by ... and expertise of law enforcement,officials; the Pharmaceutical Research ...
Cached Medicine News:Health News:BioMed Realty Trust Declares Fourth Quarter 2007 Common Stock and Preferred Stock Dividends 2Health News:Pelosi on Bush Veto of SCHIP: 'Democrats Will Not Rest Until 10 Million Children Have Access to Health Care' 2Health News:Common Infant Vaccine Recalled 2Health News:Common Infant Vaccine Recalled 3Health News:New School Curriculum Addresses Rx and OTC Drug Abuse 2Health News:New School Curriculum Addresses Rx and OTC Drug Abuse 3Health News:New School Curriculum Addresses Rx and OTC Drug Abuse 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: